|
US2021106581A1
|
|
Treatment Of Liver Diseases
|
|
US2018289707A1
|
|
Treatment of adipocytes
|
|
AU2014221302A1
|
|
Method and formulations for modulating Lyn kinase activity and treating related disorders
|
|
SG11201403207WA
|
|
Treatment of type i and type ii diabetes
|
|
AU2012227275A1
|
|
Method and formulations for modulating Lyn kinase activity and treating related disorders
|
|
WO2011150300A1
|
|
Prevention of pancreatic beta cell degeneration
|
|
NZ579227A
|
|
Methods of identifying activators of lyn kinase
|
|
CN101287467A
|
|
Methods and formulations for modulating Lyn kinase activity and treating related disorders
|
|
KR20140096141A
|
|
Methods and formulations for modulating lyn kinase activity and treating related disorders
|
